Shares of Ultragenyx Pharmaceutical (RARE) surged 5.11% on November 11th, 2024, after a bullish analyst report from TD Cowen.
Analyst Yaron Werber maintained a Buy rating on Ultragenyx and reiterated his positive outlook on the biopharmaceutical company. While the exact details of the report were not disclosed, Werber's bullish stance seems to have fueled investor confidence in Ultragenyx, driving the stock price higher.
Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases. The company has several promising drug candidates in its pipeline, and Werber's report likely highlighted the potential for these therapies to drive future growth and profitability for the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。